期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

脑胶质瘤局部缓释化疗的研究进展 被引量：3

下载PDF
导出
摘要 脑胶质瘤占中枢神经系统肿瘤的首位,是神经外科中难治性疾病之一.尽管神经外科的治疗方法有了很大的进步,但对恶性胶质细胞瘤的治疗效果仍未得到明显改善.由于胶质瘤呈浸润性生长,与正常脑组织分界不清,手术不可能彻底切除,术后常有复发,恶性胶质瘤单纯手术治疗,平均生存期仅6个月,而手术后辅以放疗平均生存期不超过一年.近10年来,在化疗方面取得了重要进展[1],但化疗药物通过常规静脉给药难以透过血脑屏障,药物在体内呈非特异性分布,而在肿瘤局部浓度较低,加大给药量又会导致全身毒副作用的增加.因此临床上迫切需要能找到解决化疗所带来的毒副作用的新方法.随着各种缓释药物的开发,为脑肿瘤局部缓释化疗提供了条件,有着良好的应用前景[2],值得进一步研究.
作者 王金环 李牧 王守伦
机构地区 [
出处 《神经疾病与精神卫生》 2001年第4期59-60,共2页 Journal of Neuroscience and Mental Health
关键词 脑胶质瘤 化疗 局部缓释 神经外科 生存期 恶性胶质瘤 胶质细胞瘤 性分 平均 常规
分类号 R739.4 [医药卫生—肿瘤]
  • 相关文献

参考文献13

  • 1Pech IV,Peterson K,Caimcross JG. Chemotherapy of brain tumors [J ]. Oncology, 1998,12:537 - 543 ;547 - 548.
  • 2Haroun RI, Brem H. Local drug delivery[J]. Curr Opin Oncol,2000,12(3): 187 - 193.
  • 3Tamargo RL, Myseros JS, Brem H. Growth inhibition of the 9L gliosarcoma by the local sustained release of BCNU: a comparision of systemic versus regional chemotherapy. Annual Meeting of the American Association of Neurological surgeons. Toronto, Canada.1988. April,24 - 28.
  • 4Brem H,Piantadosi S,Burger PC,et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for rccurrent gliomas[J].Lancet, 1995,345:1 008- 1 012.
  • 5Sipos EP,Tyler B, Piantadosi S,et al. Optimizing interstitial delivery of BCNU from controlled release polymers for the treatment of brain tumors[J ]. Cancer chemother pharmacol, 1997, 39:383 -389.
  • 6Walter KA,Cahan MA,Gur A,et al. Interstitial taxol delivery from a biodegradable polymer implant against experimental malignant glioma[ J ]. Cancer Res, 1994,54: 2 207 - 2 212.
  • 7Weingart JD, Thompson RC, Tyler B, et al. Local delivery of the topoisomerase I inhibitor camptothecin sodium prolongs survival in the rat intracranial 9L gliosarcoma model[ J ]. Int J Cancer, 1995,62: 605 - 609.
  • 8Tamargo RJ,Sills AK,Reinhard CS,et al. Interstitial dexamethasone delivery in the brain for the reduction of peritumoral edema[J ]. J Neurosurg, 1991,74:956 - 961.
  • 9Geze A,Venier- Julienne MC,Saulnier P,et al. Modulated release of IdUrd from poly(D, L - lactide - co - glycolide) microspheres by addition of poly( D, L- lactide)oligomer[ J ]. Journal of Controlled Release, 1999,58:311 - 322.
  • 10Grossman SA, Reinhard CS, Colvin OM, et al. The intracerbral distribution of BCNU delivery by surgically implanted biodegradable polymers[ J ]. J Neurosurg, 1992,76: 640 - 647.

同被引文献31

  • 1王天路,谭关子,陆利霞,熊强,熊晓辉.替莫唑胺聚乳酸微球制备工艺的研究[J].现代医药卫生,2007,23(6):933-934. 被引量：5
  • 2王忠诚.王忠诚神经外科学[M].武汉:湖北科学技术出版社,2004.475.
  • 3Stupp R, Gander M, Leyvraz S, et al. Current and future developments in the use of temozolomide for the treatment of brain tumors[J]. Lancet Oncol,2001,2(9) : 552-560.
  • 4Zhang H, Gao S. Temozolomide/PLGA microparticles and antitumor activity against Glioma C6 cancer cells in vitro[J]. Int J Pharm, 2007,329(1) : 122-128.
  • 5Allhenn D, Boushehri MA, Lamprecht A. Drug delivery strategiesfor the treatment of malignant gliomas[J]. Int J Pharmaceut, 2012,436(1-2): 299-310.
  • 6Oshiro S, Tsugu H, Komatsu F, et al. Efficacy of temozolomidetreatment in patients with high-grade glioma[J]. Anticancer Res,2009, 29(3): 911-7.
  • 7Trinh VA, Patel SP, Hwu WJ. The safety of temozolomide in thetreatment of malignancies[J]. Expert Opin Drug Saf, 2009, 8(4):493-9.
  • 8Wen PY, Kesari S. Malignant gliomas in adults[J]. N Engl J Med,2008, 359(5): 492-507.
  • 9Thorne RG, Emory CR, Ala TA, et al. Quantitative analysis of theolfactory pathway for drug delivery to the brain[J]. Brain Res,1995, 692(1/2): 278-82.
  • 10Lochhead JJ, Thorne RG. Intranasal delivery of biologics to thecentral nervous system[J]. Adv Drug Deliv Rev, 2012, 64(7):614-28.

引证文献3

二级引证文献26

神经疾病与精神卫生
2001年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部